Nicotine Prevents MPTP-induced Dopaminergic Neurodegeneration
Experimental Neurobiology
; : 95-100, 2008.
Article
de En
| WPRIM
| ID: wpr-59830
Bibliothèque responsable:
WPRO
ABSTRACT
Epidemiological studies of Parkinson disease (PD) have found an inverse correlation between cigarette smoking and the risk of developing PD, which suggests that nicotine has a protective effect. Results from animal models of PD are conflicting, raising questions about a protective potential of nicotine. In this study, mice were pretreated with low-dose nicotine before MPTP administration, and examined to determine a neuroprotective potential of nicotine. The schedule of nicotine administration was selected to simulate the future human trials using this putative neuroprotective agent. Male C57Bl/6 mice were pretreated with nicotine for 5 days (0.2 mg/kg/d, i.p.). After the 5-day-pretreatment with nicotine only, nicotine and MPTP (30 mg/kg/d, i.p.) were co-administered for 1 to 5 consecutive days. The total dose of nicotine, 0.2 mg/kg/d for 6 to 10 days, is the lowest one ever studied. Tyrosine hydroxylase (TH) immunohistochemical staining of the nigral sections was performed. Over the experimental period, there was a significant reduction in the TH-positive cells. In the nicotine-MPTP group, the degree of TH neuron depletion was reduced at days 4 and 5 of co-administration. These findings suggest that the nicotinic neurotransmission on the dopaminergic neurons are promising targets for neuroprotective therapy of PD.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Maladie de Parkinson
/
Rendez-vous et plannings
/
Tyrosine 3-monooxygenase
/
Fumer
/
1-Méthyl-4-phényl-1,2,3,6-tétrahydropyridine
/
Transmission synaptique
/
Modèles animaux
/
Neurones dopaminergiques
/
Neurones
/
Nicotine
Type d'étude:
Prognostic_studies
Limites du sujet:
Animals
/
Humans
/
Male
langue:
En
Texte intégral:
Experimental Neurobiology
Année:
2008
Type:
Article